Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PRKCD
REST API REST API
Homo sapiens
PRKCD is differentially expressed in 263 experiments: 119 organism parts: liver, mammary gland, ... (117 more);, 183 disease states: normal, breast carcinoma, ... (181 more);, 78 cell types 348 cell lines 29 compound treatments and 73 other conditions.
Orthologs Prkcd (Mus musculus)   prkcd (Danio rerio)   PRKCD (1 of 2) (Danio rerio)   PRKCD (Gallus gallus)   PRKCD (Bos taurus)   ENSCING00000000606 (Ciona intestinalis)   Prkcd (Rattus norvegicus)   Pkcdelta (Drosophila melanogaster)   prkcd (Xenopus laevis)   KPCD_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, plasma membrane, protein stabilization, protein kinase C activity, endoplasmic reticulum, protein binding, apoptosis, cytokine-mediated signaling pathway, cytoplasm, positive regulation of catalytic activity, negative regulation of peptidyl-tyrosine phosphorylation, cell-cell junction, metal ion binding, RNA metabolic process, protein tyrosine kinase activity, insulin receptor substrate binding, blood coagulation, nuclear matrix, ATP binding, nucleus, activation of phospholipase C activity, enzyme activator activity, nucleotide binding, protein serine/threonine kinase activity, protein C-terminus binding, negative regulation of MAP kinase activity, nucleoplasm, peptidyl-threonine phosphorylation, enzyme binding, signal transduction, negative regulation of insulin receptor signaling pathway, protein kinase activity, immunoglobulin mediated immune response, regulation of receptor activity, negative regulation of protein binding, mRNA metabolic process, calcium-independent protein kinase C activity, B cell proliferation, neutrophil activation, interleukin-12 production, negative regulation of inflammatory response, nerve growth factor receptor signaling pathway, interleukin-10 production, platelet activation, protein phosphorylation, intracellular signal transduction, cellular component disassembly involved in apoptosis, interferon-gamma-mediated signaling pathway, positive regulation of glucosylceramide catabolic process, positive regulation of protein dephosphorylation, positive regulation of sphingomyelin catabolic process, positive regulation of ceramide biosynthetic process, termination of signal transduction, cellular senescence
InterPro Term Pkinase_C, AGC-kinase_C, Prot_kinase_cat_dom, Prot_kin_PKC_delta, Prot_Kinase_C-like_PE/DAG-bd, DAG/PE-bd, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession C9J9P1, C9K0E3, Q05655, C9JZU8, B4DFV1
Search EB-eye ENSG00000163932
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
A549
1
2
E-GEOD-6013, E-GEOD-3202
K562
2
E-GEOD-24147, E-GEOD-96
MOLT4
2
E-MTAB-37, E-MTAB-62
SKBR3
2
E-MEXP-440, E-MTAB-62
MCF-7
1
2
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
342 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-21668, E-GEOD-20677, E-GEOD-13987, E-TABM-34, ... (38 experiments)

Factor Value U/D Experiments
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
neutrophil
2
E-GEOD-12662, E-GEOD-3982
whole blood
2
E-GEOD-3026, E-MTAB-25
CD19+ B cell
1
E-MEXP-1600
alveolar space neutrophil
1
E-GEOD-2322
kidney cell
1
E-MEXP-1216
72 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-MTAB-62, E-GEOD-5418, ... (52 experiments)

Factor Value U/D Experiments
Burkitt's lymphoma
1
3
E-MTAB-37, E-GEOD-96, E-GEOD-1880
prostate carcinoma
3
E-MTAB-62, E-MEXP-2034, E-GEOD-7307
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
neuroblastoma
2
E-MTAB-37, E-MTAB-62
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
acute promyelocytic leukemia
1
2
E-MTAB-62, E-GEOD-995, E-GEOD-96
177 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-4668, E-GEOD-6907, E-GEOD-15205, E-TABM-782, ... (23 experiments)

Factor Value U/D Experiments
none
5
6
E-TABM-782, E-GEOD-412, E-GEOD-2803, E-MEXP-1958, E-GEOD-697, ... (11 experiments)
transforming growth factor beta
1
E-GEOD-1724
vanadium pentoxide
1
E-GEOD-5339
1mM GDC-0941
1
E-GEOD-20719
mannitol
1
E-GEOD-6400
TGF
1
E-GEOD-15205
23 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-GEOD-21374, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-MEXP-2359, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-21887, E-GEOD-3013 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-17385, E-GEOD-20847, E-GEOD-2299 ... (5 experiments)

Genotype
studied in E-TABM-763, E-GEOD-1923, E-GEOD-21750, E-GEOD-2292, E-GEOD-18005, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-GEOD-1926, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-980, E-GEOD-6802, E-GEOD-360 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-23984, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-19246, E-GEOD-19815

Tumor grading
studied in E-GEOD-4290

Vehicle
studied in E-GEOD-5258

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.285 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM